Global Information
회사소개 | 문의 | 비교리스트

세균성 폐렴 : 파이프라인 리뷰

Bacterial Pneumonia - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 265421
페이지 정보 영문 212 Pages
가격
US $ 2,000 ₩ 2,408,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,816,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,224,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세균성 폐렴 : 파이프라인 리뷰 Bacterial Pneumonia - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 212 Pages

세균성 폐렴은 폐의 한쪽 또는 양쪽에 세균이 침투하여 폐포에 염증을 일으키고, 고름, 삼출액, 세포 파편으로 채워지게 하는 감염증입니다. 발병하면 산소와 이산화탄소 교환 능력이 저하됩니다. 질병 소인에는 연령, 장기간의 면역억제제 사용, 코르티코스테로이드를 장기간 복용하는 만성 폐쇄성 폐질환(COPD) 환자, 흡연자 등이 있습니다. 주요 증상은 황색·녹색 또는 피가 섞인 가래를 동반한 기침, 두통, 근육통, 호흡 곤란, 무기력, 의식 혼탁 등입니다.

세계 각국에서의 세균성 폐렴(Bacterial Pneumonia) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계에 있는 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

세균성 폐렴 개요

치료제 개발

  • 세균성 폐렴용 파이프라인 제품 : 개요
  • 세균성 폐렴용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 세균성 폐렴 치료제

각 대학/연구기관에서 연구중인 세균성 폐렴 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명확한 제품

세균성 폐렴 치료제 : 개발중인 제품 목록(기업별)

세균성 폐렴 치료제 : 연구중인 제품 목록(대학/연구기관별)

세균성 폐렴 치료제 개발에 참여하고 있는 기업

  • Abera Bioscience AB
  • Actelion Ltd
  • Alvogen Korea Co., Ltd.
  • Aridis Pharmaceuticals LLC
  • Arsanis Biosciences GmbH
  • AstraZeneca Plc
  • Beijing Minhai Biotechnology Co., Ltd
  • ContraFect Corporation
  • Daiichi-Sankyo
  • Double Bond Pharmaceutical International AB
  • Emergent BioSolutions Inc.
  • Eurocine Vaccines AB
  • FluGen, Inc.
  • GlaxoSmithKline Plc
  • Humabs BioMed SA
  • ImmunoBiology Limited
  • Indian Immunologicals Limited
  • Integrated BioTherapeutics, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lascco SA
  • LG Life Science LTD.
  • Liquidia Technologies, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Mucosis B.V.
  • Noxxon Pharma AG
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • SK Chemicals Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Valneva SE
  • Vaxxilon AG
  • Virometix AG
  • Walvax Biotechnology Co., Ltd.
  • Wellstat Vaccines, LLC
  • Wockhardt Limited

세균성 폐렴 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기전별
  • 투여 방법별
  • 분자 종류별

약제 개요

세균성 폐렴 치료제 : 휴지 상태인 프로젝트

세균성 폐렴 치료제 : 개발이 중지된 제품

세균성 폐렴 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스

부록

도표

LSH 16.09.30

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Pneumonia - Pipeline Review, H2 2016, provides an overview of the Bacterial Pneumonia (Infectious Disease) pipeline landscape.

Bacterial pneumonia is an infection in one or both lungs. The bacteria cause the lung's air sacs (alveoli) to become inflamed and engorged with pus, fluid, and cellular debris. This often impairs the body's ability to exchange oxygen and carbon dioxide. Predisposing factors are age, long-term users of immunosuppressant drugs, chronic obstructive pulmonary disease (COPD) patients who use inhaled corticosteroids for lengthy periods and smokers. Symptoms include cough with yellow, green, or blood-tinged mucus, headache, muscle pain, breathlessness or rapid breathing, lethargy and confusion.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Pneumonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 8, 13, 2, 30, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 9 and 6 molecules, respectively.

Bacterial Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Pneumonia (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Bacterial Pneumonia Overview
  • Therapeutics Development
  • Bacterial Pneumonia - Therapeutics under Development by Companies
  • Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes
  • Bacterial Pneumonia - Pipeline Products Glance
  • Bacterial Pneumonia - Products under Development by Companies
  • Bacterial Pneumonia - Products under Investigation by Universities/Institutes
  • Bacterial Pneumonia - Companies Involved in Therapeutics Development
  • Bacterial Pneumonia - Therapeutics Assessment
  • Drug Profiles
  • Bacterial Pneumonia - Dormant Projects
  • Bacterial Pneumonia - Discontinued Products
  • Bacterial Pneumonia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bacterial Pneumonia, H2 2016
  • Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Bacterial Pneumonia - Pipeline by Abera Bioscience AB, H2 2016
  • Bacterial Pneumonia - Pipeline by Actelion Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Affinivax Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Allergan Plc, H2 2016
  • Bacterial Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Arsanis Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by AstraZeneca Plc, H2 2016
  • Bacterial Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Biken Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by ContraFect Corp, H2 2016
  • Bacterial Pneumonia - Pipeline by Crestone Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
  • Bacterial Pneumonia - Pipeline by Emergent BioSolutions Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by FluGen Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Bacterial Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Lascco SA, H2 2016
  • Bacterial Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by LG Life Science LTD, H2 2016
  • Bacterial Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by MedImmune LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Merck & Co Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Mucosis BV, H2 2016
  • Bacterial Pneumonia - Pipeline by Noxxon Pharma AG, H2 2016
  • Bacterial Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Pfizer Inc, H2 2016
  • Bacterial Pneumonia - Pipeline by Polyphor Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016
  • Bacterial Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Bacterial Pneumonia - Pipeline by Valneva SE, H2 2016
  • Bacterial Pneumonia - Pipeline by Vaxxilon AG, H2 2016
  • Bacterial Pneumonia - Pipeline by Virometix AG, H2 2016
  • Bacterial Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016
  • Bacterial Pneumonia - Pipeline by Wockhardt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bacterial Pneumonia - Dormant Projects, H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..1), H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..2), H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..3), H2 2016
  • Bacterial Pneumonia - Dormant Projects (Contd..4), H2 2016
  • Bacterial Pneumonia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bacterial Pneumonia, H2 2016
  • Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top
전화 문의
F A Q